Evidence map›Paper›PMID 38055740›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

CD5L is a canonical component of circulatory IgM.

Nienke Oskam, Maurits A den Boer, Marie V Lukassen, Pleuni Ooijevaar-de Heer, Tim S Veth, Gerard van Mierlo, Szu-Hsueh Lai, Ninotska I L Derksen, Victor Yin, Marij Streutker and 14 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Structural promiscuity in the human circulatory IgA1 clonal repertoire.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Science advances · 2025
    Article
  11. Article
  12. Article
  13. Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 1 country.

Nienke Oskam *Sanquin Research and Landsteiner Laboratory, Department of Immunopathology, Amsterdam University Medical Center, Amsterdam 1066 CX, the Netherlands.
Maurits A den Boer *Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.
Marie V LukassenBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.
Pleuni Ooijevaar-de HeerSanquin Research and Landsteiner Laboratory, Department of Immunopathology, Amsterdam University Medical Center, Amsterdam 1066 CX, the Netherlands.
Tim S VethBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.
Gerard van MierloSanquin Research and Landsteiner Laboratory, Department of Immunopathology, Amsterdam University Medical Center, Amsterdam 1066 CX, the Netherlands.
Szu-Hsueh LaiBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.ORCID 0000-0001-9698-1496
Ninotska I L DerksenSanquin Research and Landsteiner Laboratory, Department of Immunopathology, Amsterdam University Medical Center, Amsterdam 1066 CX, the Netherlands.ORCID 0000-0002-0189-2675
Victor YinBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.ORCID 0000-0003-0104-0293
Marij StreutkerSanquin Research and Landsteiner Laboratory, Department of Immunopathology, Amsterdam University Medical Center, Amsterdam 1066 CX, the Netherlands.
Vojtech FrancBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.ORCID 0000-0003-4114-2382
Marta ŠiborováBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.ORCID 0000-0002-6879-5247
Mirjam J A DamenBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.
Dorien KosSanquin Research and Landsteiner Laboratory, Department of Immunopathology, Amsterdam University Medical Center, Amsterdam 1066 CX, the Netherlands.
Arjan BarendregtBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.
Albert BondtBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.ORCID 0000-0002-0985-7903
Johannes B van GoudoeverAmsterdam University Medical Center, Vrije Universiteit, University of Amsterdam, Emma Children's Hospital, Amsterdam 1105 AZ, the Netherlands.ORCID 0000-0003-3960-1703
Carla J C de HaasDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht 3584 CX, the Netherlands.
Piet C AertsDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht 3584 CX, the Netherlands.
Remy M MutsDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht 3584 CX, the Netherlands.ORCID 0000-0002-4325-1382
Suzan H M RooijakkersDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht 3584 CX, the Netherlands.ORCID 0000-0003-4102-0377
Gestur VidarssonBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.ORCID 0000-0001-5621-003X
Theo Rispens *Sanquin Research and Landsteiner Laboratory, Department of Immunopathology, Amsterdam University Medical Center, Amsterdam 1066 CX, the Netherlands.ORCID 0000-0001-9600-1312
Albert J R Heck *Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.ORCID 0000-0002-2405-4404
Utrecht University · NLSanquin · NLEmma Kinderziekenhuis · NL

Funding

Dutch Arthritis Association (Dutch Arthritis Foundation) 17-2-404Independent Research Fund Denmark 9036-00007BNederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) 184.034.019Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) SPI.2017.028
6 · The paper itself

Abstract

Immunoglobulin M (IgM) is an evolutionary conserved key component of humoral immunity, and the first antibody isotype to emerge during an immune response. IgM is a large (1 MDa), multimeric protein, for which both hexameric and pentameric structures have been described, the latter additionally containing a joining (J) chain. Using a combination of single-particle mass spectrometry and mass photometry, proteomics, and immunochemical assays, we here demonstrate that circulatory (serum) IgM exclusively exists as a complex of J-chain-containing pentamers covalently bound to the small (36 kDa) protein CD5 antigen-like (CD5L, also called apoptosis inhibitor of macrophage). In sharp contrast, secretory IgM in saliva and milk is principally devoid of CD5L. Unlike IgM itself, CD5L is not produced by B cells, implying that it associates with IgM in the extracellular space. We demonstrate that CD5L integration has functional implications, i.e., it diminishes IgM binding to two of its receptors, the FcαµR and the polymeric Immunoglobulin receptor. On the other hand, binding to FcµR as well as complement activation via C1q seem unaffected by CD5L integration. Taken together, we redefine the composition of circulatory IgM as a J-chain containing pentamer, always in complex with CD5L.

Indexed as

B-LymphocytesImmunoglobulin J-ChainsAntigensImmunoglobulin MMacrophagesAntigensImmunoglobulin J-ChainsImmunoglobulin MCD5LIgMimmunoglobulinmass spectrometrystructure

Identifiers

PMID38055740
PMCPMC10723121
OpenAlexW4389372115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.